title: The role of the glutathione-dependent system in tumor sensitivity to cisplatin: a study of human tumor xenografts.
abstract: BACKGROUND
  Glutathione, the most important intracellular thiol, has been implicated in modulating tumor cell sensitivity to alkylating agents and cisplatin. However, the role of the glutathione-dependent detoxification system in mediating cisplatin resistance of human tumors remains unclear.
  
  
  METHODS
  Glutathione content and related enzyme activities were assessed in a series of human tumor xenografts representative of responsive (i.e., small-cell lung cancer and ovarian carcinoma) and resistant tumor types (i.e., non-small-cell lung cancer and colorectal carcinoma), in an attempt to establish a correlation with response to cisplatin treatment.
  
  
  RESULTS
  The pattern of tumor response to cisplatin treatment for tumors selected in the two panels corresponded to the one expected from the clinical experience, since drug-induced tumor growth inhibition ranged from 70% to 100% in the group of sensitive tumors and from 20% to 60% in the group of resistant tumors. No correlation was observed between glutathione level and cisplatin response in the resistant tumor panel. An inverse correlation was found for glutathione-S-transferase activity level and tumor response only in the panel of chemoresponsive tumors. In the latter panel, the only unresponsive tumor (POCS) showed the highest glutathione level in the entire series investigated. No significant correlation was found between other enzymes investigated and tumor response to cisplatin treatment. In addition, a very low activity of gamma-glutamyltranspeptidase was found to be associated with sensitive tumors.
  
  
  CONCLUSIONS
  Although glutathione may have a role in modulating cisplatin cell sensitivity, it is unlikely that alteration in glutathione level and metabolism is a primary mechanism of cisplatin resistance in human tumors, since: a) no significant correlations were found between glutathione level and response to cisplatin treatment in a series of chemosensitive and chemoresistant human tumor xenografts; b) a marked increase in glutathione level might be responsible for cisplatin resistance but, in contrast to findings on cell systems selected in vitro for resistance, it is not a frequent event in human tumors.
authors.affiliation: Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pratesi
authors.forename: L
authors.initials: L
authors.lastname: Dal Bo
authors.forename: A
authors.initials: A
authors.lastname: Paolicchi
authors.forename: P
authors.initials: P
authors.lastname: Tonarelli
authors.forename: R
authors.initials: R
authors.lastname: Tongiani
authors.forename: F
authors.initials: F
authors.lastname: Zunino
mesh_terms: D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use*; D005978:Glutathione / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012680:Sensitivity and Specificity; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D005978:Glutathione; D002945:Cisplatin